STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications
SFX-01 will strengthen STALICLA’s pipeline to advance precision medicine for a new subgroup of patient with Autism Spectrum Disorder GENEVA, Oct. 10, 2022 /PRNewswire/ — STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI)…
Comments Off on STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications